$GILDGILEAD SCIENCES, INC.

📅 Upcoming

🕒 Recent(90d)

News

• DPHARM: How to address the clinical trial enrollment crisis?
  Clinical trials are facing an enrollment crisis. Around 80% of trials don’t meet their enrollment timelines, and fewer than 5% of eligible adult cancer patients participate in trials.
  fiercebiotech · 16d ago
• Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
  Cellectis may have kicked off the year promising “huge momentum” in the allogeneic CAR-T space, but even the French biotech has been unable to resist the dominance of in vivo options.
  fiercebiotech · 19d ago
• Tyra shares slip as bladder cancer responses fall short of investor expectations
  Despite falling short of analyst expectations, Tyra Biosciences is taking its cancer drug to registrational development for non-muscle invasive bladder cancer.
  biospace · 23d ago
• BMS clinches pivotal win for myeloma CAR T in ‘key derisking event’
  Bristol Myers Squibb is positioning arlo-cel for quadruple-class exposed patients, which could help reduce competition with an upcoming multiple myeloma CAR T therapy from Gilead Sciences, accordin…
  biospace · 24d ago
• This week in charts: China deals, stock flatlines and Lilly’s M&A spree
  Deals with Chinese drugmakers are continuing at a steady pace, while two mid-cap biotechs' stock prices took a tumble this week. Meanwhile, Lilly has outpaced other pharmas in dealmaking this year.
  biopharma_dive · 29d ago
• 7 biopharma M&A deals where layoffs followed
  Workforce cuts this year at seven companies involved in recent mergers and acquisitions will cost over 1,300 employees their jobs. Affected businesses include Arcellx and Tourmaline Bio, acquired b…
  biospace · 1mo ago
• Gilead looks to upcoming inflammation, cancer catalysts as pressure to diversify mounts
  HIV remained Gilead’s strongest franchise in the second quarter, but the pharma is building out its pipeline beyond virology, particularly focusing on inflammation and oncology.
  biospace · 1mo ago
• STAT+: California Supreme Court sides with Gilead in ‘duty’ to innovate case
  The California Supreme Court sided with Gilead Sciences in a closely watched case over whether the company had a "duty" to innovate.
  stat · 2mo ago
• Merck stages expanded access to monthly HIV PrEP pill ahead of approval
  Following in the footsteps of Gilead, Merck has signed voluntary licensing agreements to enable access to its investigational HIV PrEP pill alimatravir ahead of any regulatory submissions.
  fiercebiotech · 2mo ago
• Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
  Roche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker s…
  biospace · 2mo ago